Brainstorm Cell Therapeutics (STU:GHD) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


STU:GHD Brainstorm Cell Therapeutics Inc STU:GHD
28 GF Score
Price €2.98
! 3 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics ROE % Adjusted to Book Value?

Brainstorm Cell Therapeutics STU:GHD 28 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates STU:GHD with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Brainstorm Cell Therapeutics's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Brainstorm Cell Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Brainstorm Cell Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Brainstorm Cell Therapeutics ROE % Adjusted to Book Value Related Terms

Brainstorm Cell Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Brainstorm Cell Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics ROE % Adjusted to Book Value Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.71 0.00 0.00 0.00 0.00

Brainstorm Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:GHD vs ADAPY, APRE, JSPR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's ROE % Adjusted to Book Value falls into.


STU:GHD
28GF Score
Brainstorm Cell Therapeutics Inc STU:GHD
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics ROE % Adjusted to Book Value Calculation

Brainstorm Cell Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Brainstorm Cell Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Brainstorm Cell Therapeutics (STU:GHD) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Brainstorm Cell Therapeutics and its competitors.
Is Brainstorm Cell Therapeutics' ROE % Adjusted to Book Value too high?
Brainstorm Cell Therapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' ROE % Adjusted to Book Value compare to ADAPY and APRE?
Brainstorm Cell Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (STU:GHD) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Brainstorm Cell Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (STU:GHD), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Other Exchanges BCLI:USA
Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for STU:GHD

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price